Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
about
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatmentElotuzumab for the treatment of multiple myelomaSalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Novel agents in the treatment of multiple myeloma: a review about the futureTreatment of relapsed and refractory multiple myelomaMultiple myeloma in the very elderly patient: challenges and solutionsMinimal Residual Disease Assessment in the Context of Multiple Myeloma TreatmentThe Role of Immunotherapy in Multiple MyelomaEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesDevelopment of Novel Immunotherapies for Multiple MyelomaThe Danish National Multiple Myeloma RegistryThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectivePrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyRecent advances in understanding multiple myelomaRecent advances in multiple myeloma: a Korean perspectiveMagic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateTreatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumabTriplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.The next generation of novel therapies for the management of relapsed multiple myeloma.The role of SLAMF7 in multiple myeloma: impact on therapy.Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.Immunotherapy in hematologic malignancies: past, present, and future.Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myelomaAllogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.Myeloma today: Disease definitions and treatment advances.Multiple myeloma in the marrow: pathogenesis and treatments.
P2860
Q26738944-9F4187F2-21C6-4D51-ABAF-0D92139C511AQ26740278-030D5913-5E95-4AE4-A176-6D2C49816788Q26740359-4B80230C-2351-40D4-AFD0-F7092378508DQ26745924-F7D0398D-8CDA-4B1A-AF74-B1216F7F6FDFQ26749180-B07AF8F3-FFF4-44E7-A4F6-EF96A1E218C1Q26752991-BFE243B7-93CB-41E4-A991-46BDFFAA0231Q26768653-9CAEB175-049A-4977-84F9-5CF849042B35Q26771144-621EE427-579E-4F48-96B2-F1BDFD0950B9Q26771331-4BE4E64C-ADB1-47F2-8952-AD147FE58A35Q26782868-19AAC73F-DD83-4FD7-B16F-6B2E7B98CEFBQ27026478-65FB897E-C690-445B-B21B-053A85566D86Q28066890-775D349D-CE52-4F30-B967-6A265F90D631Q28067187-09559B04-9BDE-41CD-AB2D-68012116DC2FQ28069789-27E5296E-4388-4D56-B9B0-9CFD98175CBFQ28070090-2528B2BE-6CD5-4366-9460-A19AD5B7071EQ28070331-2ECC909E-91E2-46AC-9590-447D0AC86C3EQ28074521-A9353A1F-3C33-426D-8397-2198589DAD1EQ28075816-AC9E247E-BE8D-44A2-8080-5CC0DB2DBC85Q28076147-B585D4BB-F8B9-4853-A314-B0B33CFE51A2Q28078993-DC92CBFF-BB6C-4B2C-B328-101ECE06C809Q30238893-27A5AF9E-73DF-40BE-87ED-FF64F28754FCQ30239781-DA95CBE7-C574-4576-B779-BA66121A7716Q30248534-BD74D264-4CFE-45C4-BC92-2C24F5DCCEAEQ30249167-35A59033-9EC2-4855-B777-14F95FD41D04Q30249513-09A5A2AC-41F0-4FE5-A1B4-C2695C1B1961Q30275870-BB2048F7-3EE4-447D-B6AE-3923E14D7B9CQ33433453-ED02F37B-981B-4C97-A7B7-2F4EC8074C04Q33437691-DBA968F7-6432-42C7-9C41-2F4BE6F9E45EQ33437811-C03BB860-EE26-4C0D-B57C-BE7BD64D64D0Q33441476-D10D95B8-C837-4792-8770-AF7B5D80EB9EQ33441702-A100CCFB-7F1F-4F02-8FC6-E48A67B4E096Q33443406-87843BCC-9A19-4577-8766-3E435ACC3681Q33593865-4EAD9DAA-5342-412C-A1D0-A283FF1BACD3Q33785935-97EA04CD-D999-4D3E-8E44-AB99A404066CQ34551324-45B99460-D88F-48D3-AFEE-F05EDB4373E1Q34556156-ED567062-D33F-4BBD-9F27-4F4ADA43B3C7Q35789280-90CF0895-08F1-4FC4-9E89-B3DF8CC80857Q36000415-756797E6-5338-4E51-B4E0-422C5E2ADA6EQ36470699-2C000762-E935-4BC3-8BD7-55EACD90B9ABQ36725401-316C42E2-57C5-44D8-AF00-6409488E4D6C
P2860
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
@en
type
label
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
@en
prefLabel
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
@en
P2093
P50
P356
P1476
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
@en
P2093
Adam Walter-Croneck
Andrew Belch
Andrew Spencer
Anil Singhal
Christoph Röllig
Darrell White
Donna Reece
ELOQUENT-2 Investigators
Eric Bleickardt
Heather Oakervee
P304
P356
10.1056/NEJMOA1505654
P407
P50
P577
2015-06-02T00:00:00Z